GeoVax Labs, Inc. New (GOVX) — 分析摘要
GeoVax Labs, Inc. New（GOVX）的市值为2.57百万美元，最近一年的营收同比增长了-37.1%。净利润率为-862.3%。当前市盈率为-0.1倍。
核心要点
- 营收同比变化-37.1%
- 净利润率-862.3%
- 市盈率-0.1倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，GOVX的营收增长为-37.1%，市盈率为-0.1倍。
GeoVax Labs, Inc. New (GOVX)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营收较上一期下降 100.0%。
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
19
总部
SMYRNA, GA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。